Case report shows constipation risk during Cobenfy therapy in a schizoaffective disorder patient, suggesting a need for preventive strategies.
Cobenfy is a new medication for the treatment of schizophrenia. It consists of a muscarinic agonist called xanomeline and a muscarinic antagonist called trospium. However, the associated gastrointestinal side effects, especially constipation, have a potential effect on compliance. Currently, there is no widely standardized constipation prevention protocol during Cobenfy therapy. We present a case of constipation during the treatment of schizoaffective disorder with Cobenfy in a middle-aged female. We conducted a literature review on Cobenfy therapeutic management strategies and provide constipation prevention strategies.
No takes yet. Share an insight, caveat, or question.
Ezema et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: